Skip to main content

Table 2 Comparisons of clinical features and biochemical parameters between diabetic group and non-diabetic group

From: Correlations of microRNA-124a and microRNA-30d with clinicopathological features of breast cancer patients with type 2 diabetes mellitus

 

Diabetic group (n = 72)

Non-diabetic group (n = 144)

t/χ2

P value

Age (years)

52.72 ± 6.23

50.08 ± 4.76

3.113

<0.001

Family history of BC

5.56% (4)

4.17% (6)

0.458

0.647

Underlying diseases

19.44% (14)

20.83% (30)

0.057

0.811

Ratio of menopause

76.39% (55)

55.56% (80)

8.889

0.003

BMI (Kg/m2)

24.68 ± 4.74

23.21 ± 3.25

2.673

0.008

SBP (mmHg)

124.68 ± 10.35

125.36 ± 11.23

0.430

0.667

DBP (mmHg)

78.36 ± 7.93

80.57 ± 8.54

1.835

0.068

HDL-C (mmol/L)

1.21 ± 0.32

1.31 ± 0.36

1.995

0.047

LDL-C (mmol/L)

3.85 ± 0.74

3.12 ± 0.65

7.425

<0.001

TG (mmol/L)

1.32 ± 0.35

1.41 ± 0.41

1.594

0.112

TC (mmol/L)

4.45 ± 0.87

3.64 ± 0.68

7.498

<0.0001

FPG (mmol/L)

8.32 ± 0.73

5.27 ± 0.43

38.56

<0.001

2hPG (mmol/L)

14.68 ± 1.02

5.58 ± 0.47

89.810

<0.001

HbA1c (%)

10.57 ± 2.11

5.64 ± 1.57

19.320

<0.001

FIns (uU/mL)

10.14 ± 3.25

5.33 ± 1.87

6.954

<0.001

HOMA-IS

42.84 ± 14.53

60.50 ± 16.29

7.779

<0.001

HOMA-IR

3.75 ± 1.25

1.27 ± 0.50

20.750

<0.001

E2 (pg/mL)

50.20 ± 11.40

23.66 ± 8.63

19.080

<0.001

  1. Comparisons on family history of BC, underlying diseases and the ratio of menopause between the two groups were measured by χ2 test; BMI, weight (kg)/height (m2); Normal BMI, 18.5–22.9 kg/m2
  2. Diabetic group, breast cancer patients with type 2 diabetes mellitus; Non-diabetic group, breast cancer patients without type 2 diabetes mellitus
  3. BC breast cancer, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, TC total cholesterol, FPG fasting blood glucose, 2hPG 2-hour postprandial blood glucose, HbA1c glycosylated hemoglobin, FIns fasting insulin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-IS HOMA of β-cell insulin secretion, E 2 estradiol